Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Unternehmen & Branche
| Name | PLUS THERAPEUTICS, INC. |
|---|---|
| Ticker | PSTV |
| CIK | 0001095981 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 3841 · Surgical & Medical Instruments & Apparatus |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 14,1 Mio. USD |
| Beta | 1,02 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 5,213,000 | -22,386,000 | -0.29 | 16,325,000 | 3,996,000 |
| 2025-09-30 | 10-Q | 1,397,000 | -4,423,000 | -0.04 | 18,670,000 | 5,054,000 |
| 2025-06-30 | 10-Q | 1,390,000 | 5,151,000 | -0.01 | 10,350,000 | 3,034,000 |
| 2025-03-31 | 10-Q | 1,059,000 | -17,401,000 | -1.19 | 12,056,000 | -23,641,000 |
| 2024-12-31 | 10-K | 5,824,000 | -12,978,000 | -2.34 | 6,633,000 | -8,949,000 |
| 2024-09-30 | 10-Q | 1,456,000 | -2,874,000 | -0.37 | 6,978,000 | -5,174,000 |
| 2024-06-30 | 10-Q | 1,279,000 | -2,940,000 | -0.71 | 11,212,000 | -7,625,000 |
| 2024-03-31 | 10-Q | 1,677,000 | -3,261,000 | -0.75 | 5,621,000 | -4,837,000 |
| 2023-12-31 | 10-K | 4,913,000 | -13,316,000 | -4.24 | 11,388,000 | -1,348,000 |
| 2023-09-30 | 10-Q | -3,219,000 | -1.00 | 13,278,000 | 2,622,000 | |
| 2023-06-30 | 10-Q | -1,482,000 | -0.59 | 14,197,000 | 2,662,000 | |
| 2023-03-31 | 10-Q | -4,805,000 | -2.07 | 15,638,000 | 2,676,000 | |
| 2022-12-31 | 10-K | -20,275,000 | -11.58 | 23,867,000 | 6,445,000 | |
| 2022-09-30 | 10-Q | -5,219,000 | -2.85 | 23,104,000 | 11,404,000 | |
| 2022-06-30 | 10-Q | -5,282,000 | -3.56 | 21,271,000 | 9,679,000 | |
| 2022-03-31 | 10-Q | -4,116,000 | -0.19 | 24,516,000 | 14,642,000 | |
| 2021-12-31 | 10-K | -13,399,000 | -1.11 | 21,981,000 | 10,836,000 | |
| 2021-09-30 | 10-Q | -3,724,000 | -0.28 | 24,750,000 | 14,755,000 | |
| 2021-06-30 | 10-Q | -2,800,000 | -0.25 | 20,834,000 | 11,945,000 | |
| 2021-03-31 | 10-Q | -2,720,000 | 18,336,000 | 9,513,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-11-04 | Sims Andrew John Hugh MacIntyre | Officer, Chief Financial Officer | Open Market Purchase | 20,000 | 0.51 | 10,200.00 | +100,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.